proliferation, especially in mesenchymal CTC-negative patients (P = .001). In low-risk patients, characterized by low Ki-67 and mesenchymal CTC absence, ADAM23 hypermethylation was an independent predictor of DFS (P = .006). Our results indicate that ADAM23 is likely involved in BC progression and dissemination of mesenchymal CTC. ADAM23 methylation has the potential to function as a novel prognostic marker and therapeutic target.
| INTRODUC TI ON
Breast cancer (BC), accounting for 15.6% of all cancer deaths in the European Union (EU), is the most common female malignancy. In 2015, Slovakia recorded the second highest standardized death rate for BC among the EU Member States (40.6 per 100 000 women).
1
Despite relatively effective treatment, metastatic disease is responsible for most patient deaths with distant metastases preferentially localized in bone, lung, liver and brain. 2, 3 It is known that epigenetic deregulation, including aberrant DNA methylation, plays an important role in BC development and progression, mainly by affecting expression of specific genes. Therefore, aberrant cancer-specific methylation patterns can serve as diagnostic and prognostic markers. [4] [5] [6] In addition, increased proliferative activity characterized by nuclear antigen Ki-67 determination is typical for malignant breast tumors.
7 Several studies confirmed the prognostic value of Ki-67 expression when high rates of Ki-67 were associated with reduced survival and aggressive tumor features. 8, 9 One of the key invasive tumor characteristics is the ability to release cancer cells from the primary tumor site. Circulating tumor cells (CTC) are individual cells or cell clusters that have detached and entered the vascular system, although only very few aggressive subpopulations have the potential to initiate the formation of metastases. 10, 11 The presence of CTC in peripheral blood of BC patients represents a strong prognostic and predictive factor and is associated with development of distant metastases, decreased survival and response to treatment. 12-16. Accumulating evidence points to a critical role of an epithelialmesenchymal transition (EMT) in metastatic progression. 17, 18 During EMT, epithelial cancer cells lose epithelial (E-cadherin, desmoplakin, cytokeratins etc.) and gain mesenchymal (N-cadherin, vimentin, fibronectin etc.) marker expression. They turn into motile mesenchymal cells with invasive and metastatic properties, and some of them also gain cancer stem cell (CSC) characteristics. [19] [20] [21] [22] [23] Therefore, commonly used CTC identification strategies exclusively based on epithelial marker detection omit patients who have the most aggressive CTC subpopulations with the mesenchymal phenotype in their peripheral blood. 24 It has been shown in several studies that mesenchymal CTC presence strongly correlates with worse prognosis and risk of developing distant metastases compared to epithelial CTC. 25, 26 A Disintegrin And Metalloprotease (ADAM) proteins, consisting of multiple domains, operate in various processes such as ectodomain shedding of growth factors, cytokines or receptors, cleavage and remodeling of extracellular matrix proteins and adhesive activities through their disintegrin and cysteine-rich domains. 27 Among 21 human ADAM proteins, ADAM23 belongs to a non-catalytic group because of its inactive metalloprotease domain. 28, 29 However, ADAM23 has been shown to have specific binding affinity for α V β 3 integrin, which is mediated by a short amino acid sequence present in its putative disintegrin loop.
Through its disintegrin-like domain, ADAM23 may function as an adhesion molecule involved in α V β 3 -mediated cell interactions occurring in normal and pathological processes. 30 In addition to α V β 3 , 31, 33 and association between ADAM23 methylation and clinical characteristics has been previously observed in BC patients. 31, 33, 39, 40 In the present study, we evaluated the prognostic significance of ADAM23 promoter methylation for hematogenous spread and disease-free survival (DFS).
| MATERIAL S AND ME THODS

| Patients
All analyses were carried out on samples of 203 invasive BC patients, (n = 175) invasive ductal, 11.3% (n = 23) invasive lobular and 2.5%
(n = 5) tubular or mucinous carcinomas. Histological grade 3 was diagnosed in 37.2% (n = 74), hormone receptor negativity in 16.5%
(n = 33), human epidermal growth factor receptor 2 (HER2) positivity (HER2+) in 15.8% (n = 32) and high Ki-67 proliferation (cut-off 20%) in 42.6% (n = 86) of patients. CTC positivity was detected in 22.9% (n = 44) of patients, of which epithelial CTC were present in 9.2% (n = 14), mesenchymal CTC in 15.8% (n = 27) and both epithelial and mesenchymal CTC in 1.6% (n = 3) of patients. 
| Detection of CTC in peripheral blood
| Pyrosequencing
The ADAM23 promoter methylation level was measured by the quantitative pyrosequencing method as published elsewhere. 43 In brief, the region of interest was amplified from bisulfite-modified DNA using amplification primers (Forward Biotin-GCGTCGTTTTAGTATTTTTAGGTT;
Reverse TCCCCAACCACTACTCCCT) and PyroMark PCR kit (Qiagen).
After purification and denaturation, the biotinylated PCR product (89 bp) was sequenced (Pyrosequencing primer: ACTACTCCCTCCCCC)
by Pyromark Q24 Pyrosequencing System (Qiagen). Obtained raw data were analyzed using PyroMark Q24 2.0.6 software (Qiagen). The results are presented as percentage of average methylation in eight CpG sites. The cut-off for ADAM23 hypermethylation (9.53%) was established in our previous study as the mean methylation level determined in normal mammary glands plus 2 SD. 
| Immunohistochemistry
Immunohistochemistry (IHC) analysis was used to detect ADAM23 protein expression in the FFPE tumor tissues. Representative tumor areas were identified by hematoxylin and eosin staining and inserted into donor and recipient blocks. The 5-μm sections were transferred to coated slides and, after deparaffinization and rehydration, they were incubated overnight with specific antibody against the ADAM23 protein (ab101638; Abcam, Cambridge, UK) and immunostained as described previously. 43 Evaluation of IHC results was carried out in parallel by two pathologists. In brief, the percentage of positive cells was scored according to the following standard: 0 (0%), 1 (1%-10%), 2 (11%-50%), 3 (51%-80%) and 4 (81%-100%). Staining intensity of the cytoplasm was graded as follows: 0 (no staining), 1
(weakly stained, 1%-30%), 2 (moderately stained, 31%-70%), and 3
(strongly stained, 71%-100% 
| RE SULTS
| ADAM23 promoter methylation and protein expression
Negative ADAM23 protein expression was identified in 24.5%
(n = 49) of tumor tissues, and weak, moderate or high expression was present in 7.5% (n = 15), 25.5% (n = 51) and 42.5% (n = 85) of tumors, respectively. As shown in Figure 1 , DNA methylation levels were approximately equally distributed across the individual protein expression categories (10.6 ± 13.2% for negative, 6.8 ± 7.0% for weak, 11.1 ± 13.0% for moderate and 9.5 ± 10.7% for high expression). Mean ADAM23 promoter methylation was 9.8 ± 11.7%.
| ADAM23 methylation and hematogenous dissemination
Based on the presence of individual CTC subpopulations in patient peripheral blood, these were stratified into four groups: CTC negative (n = 146); epithelial CTC (expression of epithelial marker KRT19 in peripheral blood, n = 14); mesenchymal CTC (expression of either TWIST1 or SLUG; SNAI1 and ZEB1 mRNA transcripts were not expressed, n = 27); and both CTC (expression of both, epithelial and EMT markers, n = 3). DNA methylation of ADAM23 significantly varied between studied groups (P = .002), with the highest level in CTC-negative patients (11.3 ± 12.9%) and decreasing mean methylation values ranging from 6.5 ± 5.5% for epithelial CTC, 4.4 ± 2.0%
for mesenchymal CTC, and 4.0 ± 1.0% for both CTC (Figure 2 ). There was strong evidence of a substantial difference between the CTCnegative and mesenchymal CTC-positive patients (P = .006, adjusted using the Bonferroni correction). In the CTC-negative group and in was nearly threefold more likely in patients whose Ki-67 proliferation was above 20% (OR = 2.995; 95% CI, 1.322-6.784; P = .009; Table 1 ).
Because patient stratification by mesenchymal CTC negativity/positivity versus complete CTC negativity/mesenchymal CTC positivity yielded almost the same results (Table S1 ), stratification by mesenchymal CTC was chosen for the next analyses with the intention not to omit patients with epithelial CTC.
DNA methylation of ADAM23 promoter was significantly higher in mesenchymal CTC-negative than in mesenchymal CTC-positive patients (10.9 ± 12.5% vs 4.4 ± 1.9%; P = .001) (Figure 3 ). This difference was even more pronounced in subjects with high Ki-67 (15.9 ± 17.0% vs 4.3 ± 1.6%; P = .001). ADAM23 promoter methylation positively correlated with Ki-67 proliferation (r = 0.163, P = .020), especially in mesenchymal CTC-negative patients (r = 0.272, P = .001). TA B L E 1 Risk estimation of ADAM23 methylation and clinical status for the presence of mesenchymal CTC in peripheral blood of breast cancer patients (logistic regression adjusted for age) 
| ADAM23 methylation and disease-free survival
F I G U R E 3
| D ISCUSS I ON
A Disintegrin And Metalloprotease proteins have been shown to play a significant role in tumor growth and metastasis. 29 In comparison with other family members, the biological role of ADAM23, especially in cell adhesion and cell-matrix interactions, largely depends on its disintegrin domain, whereas its metalloprotease domain remains inactive. 45 The ADAM23 gene is epigenetically silenced in various cancers, including BC, where it correlates with disease progression 33, 46 and lower survival rates. 31 In our previous study, carried out on almost the same set of BC patients (including three metastatic patients), we analyzed the association of DNA methylation changes in 11 genes, including ADAM23, with clinicopathological characteristics. We identified a twofold higher level of ADAM23 promoter methylation in BC patient tumors than in normal mammary glands (10.01% vs 4.89%). 39 In primary breast tumors, ADAM23 hypermethylation was associated with higher proliferation of cancer cells measured through Ki-67 expression (OR 5.23, 95% CI: 2.27-12.05, P < .001). In addition to high Ki-67 proliferation, significantly higher mean ADAM23 methylation was also identified in tumors of estrogen receptor (ER) and HER2-positive patients (12.24% vs 7.19% in Ki-67-low, P = .008;
11.25% vs 6.37% in ER-negative, P = .001; and 16.81% vs 8.76% in HER2-negative, P = .001, respectively). The presence of ADAM23 hypermethylation in tumors and lymph nodes was equally common (24.2% vs 21.6%) and positively correlated (r = 0.442, P = .001).
Higher ADAM23 promoter methylation in lymph nodes was identified in histological grade 3, HER2-positive and progesterone receptor (PGR)-negative patients (12.64% vs 6.41% in grades 1 and 2, P < .001;
15.00% vs 7.02% in HER2-negative, P < .001; and 15.00% vs 7.81%
in PGR-positive, P < .001, respectively). However, we did not find any association between ADAM23 methylation and protein expression. 39 In our recent study, we detected an association between low ADAM23 promoter methylation and hematogenous spread. (also termed SLUG), TWIST1/2 and ZEB1/2. These suppress expression of key epithelial genes, such as CDH1, coding for adherence junction protein E-cadherin. 47 CTC with mesenchymal phenotype can be detected in the peripheral circulation of BC patients through mRNA expression of EMT-inducing transcription factors. 42, 48, 49 Their presence in BC patient peripheral blood was associated with worse prognosis 25, 26 (Mego et al, in preparation) . Herein, we have
shown an association between ADAM23 promoter methylation and mesenchymal CTC, detected by the above-mentioned method. We identified lack of ADAM23 methylation in tumors of patients with mesenchymal CTC in their peripheral blood. However, we have not found correlation between ADAM23 protein expression and DNA methylation or hematogenous spread. 39, 41 One of the possible explanations could be the recently described intratumoral heterogeneity of ADAM23 protein expression observed in BC. 46 As shown by these authors, the topographically distinct invasive tumor areas within undifferentiated invasive ductal carcinomas are composed of a mosaic cluster of ADAM23-positive and ADAM23-negative tumor cells.
Furthermore, diverse ADAM23 expression in tumor-derived endothelium could be another confounding factor explaining the negative findings. 50 As DNA methylation is cell type-specific, the results of DNA methylation assessment are currently based on bulk analyses of heterogeneous cell populations interpreting their mixture averages.
Moreover, it was shown that a threshold of 40%-60% of methylated CpG dinucleotides was required for complete ADAM23 mRNA expression silencing in BC cell lines, whereas in colorectal cancer cells, it was 70%-90%. 33, 51 However, only 4.4% (n = 9) of our patients had a mean level of DNA methylation in tumor above 40% (42%-61%).
Our current findings show that ADAM23 hypermethylation increases the risk of disease recurrence in mesenchymal CTC-negative patients with low Ki-67 proliferation. We can only speculate that low ADAM23 methylation levels in tumors of mesenchymal CTC-positive patients is a result of gradual accumulation of ADAM23 methylation in distinct tumor cell subclones and subsequent release of TA B L E 2 Cox regression analysis in the group of low-risk (Ki-67-low and mesenchymal CTC-negative) breast cancer patients 
46
This type of epigenetic plasticity was recently also observed in one of the EMT hallmarks -E-cadherin loss. 52 It was shown that E-cadherin loss may promote invasion, allowing cells with the highest methylation density and the most diminished protein expression to dissociate from the primary tumor and disseminate through the vascular system to a distal, secondary organ site. In contrast, partial restoration of E-cadherin expression mediated by the evolution of cells with reduced methylation increases intercellular adhesion and may facilitate cell survival within metastatic deposits. 52 The intratumoral heterogeneity described for ADAM23 expression, 46 as well as the dynamic epigenetic heterogeneity during metastatic progression described for CDH1, 52 highlights the importance of DNA methylation changes and fine-tuning of the methylome leading to corresponding alterations in individual steps of the metastatic cascade.
Although direct association between ADAM23 and EMT has not yet been published, ADAM23 has been shown to be a key suppressor for cardiac hypertrophy and fibrosis by blocking the focal adhesion kinase-protein kinase B (FAK-AKT) signaling cascade. 53 The authors hypothesize that ADAM23 can directly affect the pathogenesis of fibrosis through the same downstream target. FAK, identified as one of the first integrin signaling molecules, is a non-receptor tyrosine kinase, required for the transcriptional regulation of several mesenchymal markers and for the delocalization of E-cadherin. 54 The α V β 3 integrin is an β3 integrin subtype that was associated with EMT in cancer cells and shows the widest range of functions, including FAKinduced actin cytoskeleton remodeling and FAK-dependent cytokine activation, affecting cell migration and invasion. 55 Activation of α V β 3 has been reported to upregulate Slug and facilitate anchorageindependent growth in pregnant and neoplastic mammary glands 56 whereas ADAM23 knockdown cells showed increased migration and adhesion to classic α V β 3 integrin ligands. 31 Additionally, downregulation of ADAM23 in a side population of lung adenocarcinoma cells contributed to the CSC phenotype, supposedly by promoting activity of α V β 3 integrin. 57 These findings support the hypothesis that by binding to integrins, namely α V β 3 and α4 and/or other cell-surface molecules, ADAM23 can act as a mediator of intercellular association and participate in facilitating EMT in cancer cells. 31, 32 To the best of our knowledge, this is the first study showing We would like to acknowledge our collaborators: Daniel Pindak, Gabriela Sieberova, Jan Macuch, Michal Majercik, Peter Jani and Dusan
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